vs
Side-by-side financial comparison of BXP, Inc. (BXP) and Insulet Corporation (PODD). Click either name above to swap in a different company.
BXP, Inc. is the larger business by last-quarter revenue ($872.1M vs $783.7M, roughly 1.1× Insulet Corporation). BXP, Inc. runs the higher net margin — 15.3% vs 13.0%, a 2.3% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (31.2% vs 0.8%). Over the past eight quarters, Insulet Corporation's revenue compounded faster (33.2% CAGR vs 1.3%).
BXP Inc., operating as Boston Properties, is a leading U.S. real estate investment trust focused on owning, managing and developing high-quality Class A commercial office properties across major U.S. metro markets, serving diverse corporate, tech and professional service tenants.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
BXP vs PODD — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $872.1M | $783.7M |
| Net Profit | $133.0M | $101.6M |
| Gross Margin | — | 72.6% |
| Operating Margin | — | 18.7% |
| Net Margin | 15.3% | 13.0% |
| Revenue YoY | 0.8% | 31.2% |
| Net Profit YoY | 53.0% | 0.9% |
| EPS (diluted) | $1.69 | $1.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $872.1M | — | ||
| Q4 25 | $877.1M | $783.7M | ||
| Q3 25 | $871.5M | $706.3M | ||
| Q2 25 | $868.5M | $649.1M | ||
| Q1 25 | $865.2M | $569.0M | ||
| Q4 24 | $858.6M | $597.5M | ||
| Q3 24 | $859.2M | $543.9M | ||
| Q2 24 | $850.5M | $488.5M |
| Q1 26 | $133.0M | — | ||
| Q4 25 | $248.4M | $101.6M | ||
| Q3 25 | $-121.7M | $87.6M | ||
| Q2 25 | $89.0M | $22.5M | ||
| Q1 25 | $61.2M | $35.4M | ||
| Q4 24 | $-228.9M | $100.7M | ||
| Q3 24 | $83.6M | $77.5M | ||
| Q2 24 | $79.6M | $188.6M |
| Q1 26 | — | — | ||
| Q4 25 | 58.8% | 72.6% | ||
| Q3 25 | 59.3% | 72.2% | ||
| Q2 25 | 59.2% | 69.7% | ||
| Q1 25 | 59.2% | 71.9% | ||
| Q4 24 | 59.7% | 72.1% | ||
| Q3 24 | 59.5% | 69.3% | ||
| Q2 24 | 59.8% | 67.7% |
| Q1 26 | — | — | ||
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 11.2% |
| Q1 26 | 15.3% | — | ||
| Q4 25 | 28.3% | 13.0% | ||
| Q3 25 | -14.0% | 12.4% | ||
| Q2 25 | 10.2% | 3.5% | ||
| Q1 25 | 7.1% | 6.2% | ||
| Q4 24 | -26.7% | 16.9% | ||
| Q3 24 | 9.7% | 14.2% | ||
| Q2 24 | 9.4% | 38.6% |
| Q1 26 | $1.69 | — | ||
| Q4 25 | $1.56 | $1.42 | ||
| Q3 25 | $-0.77 | $1.24 | ||
| Q2 25 | $0.56 | $0.32 | ||
| Q1 25 | $0.39 | $0.50 | ||
| Q4 24 | $-1.46 | $1.38 | ||
| Q3 24 | $0.53 | $1.08 | ||
| Q2 24 | $0.51 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $512.8M | — |
| Total DebtLower is stronger | — | $930.8M |
| Stockholders' EquityBook value | $7.7B | $1.5B |
| Total Assets | $25.1B | $3.2B |
| Debt / EquityLower = less leverage | — | 0.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $512.8M | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $861.1M | — | ||
| Q2 25 | $447.0M | — | ||
| Q1 25 | $398.1M | — | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $685.4M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | $7.7B | — | ||
| Q4 25 | $5.1B | $1.5B | ||
| Q3 25 | $5.0B | $1.4B | ||
| Q2 25 | $5.3B | $1.5B | ||
| Q1 25 | $5.3B | $1.3B | ||
| Q4 24 | $5.4B | $1.2B | ||
| Q3 24 | $5.8B | $1.1B | ||
| Q2 24 | $5.8B | $998.4M |
| Q1 26 | $25.1B | — | ||
| Q4 25 | $26.2B | $3.2B | ||
| Q3 25 | $26.0B | $3.0B | ||
| Q2 25 | $25.6B | $3.5B | ||
| Q1 25 | $25.4B | $3.5B | ||
| Q4 24 | $26.1B | $3.1B | ||
| Q3 24 | $26.4B | $3.0B | ||
| Q2 24 | $25.5B | $2.9B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $183.3M |
| Free Cash FlowOCF − Capex | — | $48.2M |
| FCF MarginFCF / Revenue | — | 6.2% |
| Capex IntensityCapex / Revenue | 1.5% | 17.2% |
| Cash ConversionOCF / Net Profit | — | 1.80× |
| TTM Free Cash FlowTrailing 4 quarters | — | $377.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $407.8M | $183.3M | ||
| Q3 25 | $274.2M | $125.7M | ||
| Q2 25 | $353.1M | $196.5M | ||
| Q1 25 | $210.0M | $63.8M | ||
| Q4 24 | $383.7M | $147.7M | ||
| Q3 24 | $286.1M | $98.5M | ||
| Q2 24 | $367.1M | $96.5M |
| Q1 26 | — | — | ||
| Q4 25 | $362.7M | $48.2M | ||
| Q3 25 | $231.6M | $100.1M | ||
| Q2 25 | $281.5M | $177.9M | ||
| Q1 25 | $152.6M | $51.5M | ||
| Q4 24 | $312.5M | $94.1M | ||
| Q3 24 | $234.5M | $71.8M | ||
| Q2 24 | $332.4M | $74.0M |
| Q1 26 | — | — | ||
| Q4 25 | 41.4% | 6.2% | ||
| Q3 25 | 26.6% | 14.2% | ||
| Q2 25 | 32.4% | 27.4% | ||
| Q1 25 | 17.6% | 9.1% | ||
| Q4 24 | 36.4% | 15.7% | ||
| Q3 24 | 27.3% | 13.2% | ||
| Q2 24 | 39.1% | 15.1% |
| Q1 26 | 1.5% | — | ||
| Q4 25 | 5.1% | 17.2% | ||
| Q3 25 | 4.9% | 3.6% | ||
| Q2 25 | 8.2% | 2.9% | ||
| Q1 25 | 6.6% | 2.2% | ||
| Q4 24 | 8.3% | 9.0% | ||
| Q3 24 | 6.0% | 4.9% | ||
| Q2 24 | 4.1% | 4.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.64× | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | 3.97× | 8.73× | ||
| Q1 25 | 3.43× | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | 3.42× | 1.27× | ||
| Q2 24 | 4.61× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BXP
| Lease | $818.2M | 94% |
| Parking and other | $30.8M | 4% |
| Development and management services | $9.2M | 1% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
